Desensitization therapy for allergic reactions to antituberculous drugs

Internal Medicine

Volumn 49, Issue 21, 2010, Pages 2297-2301

  Kobashi, Yoshihiro ^a   Abe, Takahiro ^b   Shigeto, Eriko ^c   Yano, Shuichi ^d   Kuraoka, Toshihiko ^e   Oka, Mikio ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b National Hospital Organization   (Japan)

^c National Hiroshima Hospital   (Japan)

^d National Hospital Organization   (Japan)

^e Yoshijima Hospital   (Japan)

Author keywords

Adverse reaction; Anti mycobacterial drugs; Desensitizaiton therapy

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; DESENSITIZATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG TUBERCULOSIS; LYMPHANGITIS; MALE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS PLEURISY;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 78249245986     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3590     Document Type: Article

References (16)

1. Japanese Society for Tuberculosis. Desensitization therapy of antituberculous drugs. Kekkaku 72: 697-700, 1997 (in Japanese).
2. Kobashi Y, Okimoto N, Matsushima T, et al. Desensitization therapy for antituberculous drugs. Kekkaku 75: 521-526, 2000 (in Japanese).
3. Kobashi Y, Okimoto N, Matsushima T, et al. Desensitization ther-apyapy for allergic reactions of antituberculous drugs. Kekkaku 75: 699-704, 2000 (in Japanese).
4. Matz J, Borish LC, Routes JM, et al. Oral desensitization to rifampicin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med 149: 815-817, 1994.
5. Holland CL, Malasky C, Ogunkoya A, et al. Rapid oral desensitization to isoniazid and rifampin. Chest 98: 1518-1519, 1990.
6. Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data revised American Thoracic Society/CDC recommendations against the use of rifampicin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 52: 735-739, 2003.
7. Schaberg T, Rebhan K, Lode H, et al. Risk factor for side-effects of isoniazid, rifampicin and pyrazynamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9: 2026-2030, 1996.
8. Kobashi Y, Niki Y, Kawane H, et al. Adverse reactions of antituberculous agents. Kekkaku 73: 485-490, 1998 (in Japanese).
9. Holland CL, Malasky C, Ogunkoya A, Bielory L. Rapid oral desensitization to isoniazid and rifampin. Chest 98: 1518-1519, 1990.
10. Matz J, Borish LC, Routes JM, Rosenwasser LJ. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med 149: 815-817, 1994.
11. Borish L, Tamir R, Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol 80: 314-319, 1987.
12. Wendel GD, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 312: 1229-1232, 1985.
13. Schreiber J, Zissel G, Greinert U, et al. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs. Eur J Med Res 4: 67-71, 1999.
14. Hurdle JG, Lee RB, Budha NR, et al. A microbiological assessment of novel nitrofuranyelamides as anti-tuberculosis agents. J Antimicrob Chemother 62: 1037-1045, 2008.
15. Stover CK, Phan XQ, Erwin AL, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966, 2000.
16. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinolone drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227, 2005.